Table 2.

Virus-neutralizing antibody (MN₅₀) titers in marmosets before and after ZIKV challenge^a.

ID	Treatment	0 weekb	2 weeksb	6 weeksb	Challengec	-7 to -5d	9 dpid	14 dpid
C1	None	N.Ae	N.Ae	N.Ae	0	0.7	1.56	3.26
V1	ZPIV 2x	0.7	1.81	3.68	20	2.24	4.79	>3.86f
V2	ZPIV 2x	0.7	2.36	N.Tg	26	2.95	3.80	>3.86f
V3	ZPIV 2x	0.7	1.64	3.61	36	2.60	3.70	>3.86f
V4	ZPIV 2x	0.7	2.50	3.70	72	2.77	4.33	4.90
GMTh	–	0.7	2.05	3.72	–	2.62	4.13	4.1
95% C.Ii	–	(0.7)	(1.5–2.8)	(3.4–4.1)	–	(2.2–3.2)	(3.4–5.0)	(3.4–4.9)

^aLog-transformed reciprocal serum dilution achieving 50% neutralization of virus.

^bWeeks after prime dose vaccination.

^cAll marmosets were i.m. challenged with ZIKV-BR at indicated weeks after prime dose vaccination.

^dDays after infection with ZIKV-BR.

^eN.A., Not applicable.

^fThe last serum dilution achieved >50% of neutralization.

^gN.T., Not tested.

^hGMT, geometric mean.

ⁱC.I. confidence interval.